Navigation Links
Varian Medical Systems to Exhibit the Latest X-Ray Image Detectors, X-Ray Tubes, and Cancer Treatment Technologies at RSNA This Year
Date:11/24/2008

arian will also exhibit its X-ray tubes for medical and industrial imaging. Varian Interay, a wholly-owned subsidiary that offers medical X-ray tubes "on demand" for the service and assembler markets, will display a wide range of X-ray tubes, including new replacements for Siemens, Philips, and GE imaging systems.

CANCER TREATMENT TECHNOLOGIES

At RSNA, Varian is introducing OncoView(TM), a specialized PACS product for viewing, managing and storing images and data needed for every phase of cancer treatment. "OncoView is an important addition to our product offerings for cancer clinics offering advanced forms of image-guided radiotherapy and radiosurgery," said Karla Knott, senior director of marketing for Varian's Oncology Systems business. "It integrates the viewing, managing, storing, and archiving of oncology images and data, supporting workflow specific to oncology at every phase of cancer treatment, from initial diagnosis to treatment response, and on to survivorship."

In addition, Varian will showcase a range of cancer treatment technologies, as well as the company's software solutions for information management and radiation therapy treatment planning.

A NEW EXHIBIT

"Visitors to our new, expanded booth will be able to see the full spectrum of Varian products and technology," said Elaine Fairless, corporate marketing and communications manager. In addition to product displays, the new two-story booth includes expanded areas for meeting with customers.

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncolog
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
2. New platinum-phosphate compounds kill ovarian cancer cells
3. Protein compels ovarian cancer cells to cannibalize themselves
4. Top Indian Cancer Hospital to Introduce Advanced Radiosurgery Treatments With Novalis Tx from Varian Medical Systems and BrainLAB
5. Varian Medical Systems Schedules Fiscal Year End Review in New York
6. Clinicians in Netherlands Treat Lung Cancer Patients Using New RapidArc Radiotherapy Technology from Varian Medical Systems
7. Ovarian and Endometrial Cancer Patients Experience Improved Outcomes When Treated First by a Gynecologic Oncologist
8. Newly found gene variants account for kidney diseases among African-Americans
9. Varian Medical Systems Signs Collaboration Agreement to Bring Advanced Radiotherapy Equipment to Indonesia
10. LOreal Paris Continues Passionate Commitment to Ovarian Cancer Research and Awareness Programs in 2008
11. Genetic variants associated with vitamin B12
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Pharmacy Technician Employment Increasing Up to 32% By 2016 2Antiabortion Advocate Appointed to Senior Position at HHS 48015 1Antiabortion Advocate Appointed to Senior Position at HHS 48015 2Special Ed Services Lacking for Kids Who Repeat a Grade 48011 1Special Ed Services Lacking for Kids Who Repeat a Grade 48011 2Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 1Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 2Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 3Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 4Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 5Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 6Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 7Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 8Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 9Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 10Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 48007 11
Other Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6